When a trade dispute reaches the pharmacy counter, the stakes become unusually personal. Washington has placed Canada’s patented-medicine pricing system among its complaints ahead of the 2026 review of the Canada–United States–Mexico Agreement, arguing that Canadian benchmarking rules undervalue American pharmaceutical innovation. At the centre is the Patented Medicine Prices Review Board, the federal body created to guard against excessive patented-drug prices.
The dispute is not simply about whether medicines should cost more or less. It involves patient access, public and private insurance budgets, research investment and the negotiating power of a country whose pharmaceutical market is far smaller than that of the United States. Canada’s own data show that its prices remain high relative to many peer countries, while still sitting dramatically below U.S. levels. That gap is now being treated in Washington not only as a health-policy difference, but as a trade irritant.
Washington Turns Drug Pricing Into a Trade Issue
The U.S. Trade Representative’s 2026 report on foreign trade barriers says Canada excludes the United States and Switzerland from the group of countries used to compare patented-medicine prices. It records the pharmaceutical industry’s view that this choice artificially lowers the value assigned to innovative drugs in Canada. The timing matters: the complaint has resurfaced as the three CUSMA partners prepare for the agreement’s first six-year joint review, giving Washington another venue in which to press longstanding grievances.
Still, the report is an inventory of alleged barriers, not a legal finding that Canada has violated CUSMA. As of June 30, the United States had not opened a pharmaceutical-pricing Section 301 investigation against Canada. It has, however, launched one against Germany and previously negotiated a pharmaceutical agreement with the United Kingdom. Those actions show that the administration is prepared to connect drug pricing with tariffs and market access. Canada therefore cannot assume the complaint is symbolic, even though no formal case has yet been announced.
Canada’s Watchdog Does Less Than Many Assume
The PMPRB is often described as a body that sets Canadian drug prices, but its legal role is narrower. It monitors the factory-gate prices charged by patent holders and may investigate when a price appears potentially excessive. Companies do not need the board’s approval before selling a medicine, and the board does not decide whether a provincial plan or private insurer will cover it. Those functions belong to Health Canada, Canada’s Drug Agency, the pan-Canadian Pharmaceutical Alliance and individual drug plans.
Under the guidelines that took effect on January 1, 2026, staff use a two-stage review. An initial or annual screen identifies medicines that may require closer examination. An in-depth review can then consider international prices, comparable therapies and the circumstances of the medicine. Only a hearing panel can determine that a price is excessive and order a reduction or repayment of excess revenue. For a patient waiting on coverage, that distinction matters: regulatory approval, price oversight, reimbursement assessment, negotiation and formulary listing are separate steps, even though delays at any stage can feel like one long process.
Why the United States Was Removed From the Benchmark
Canada changed its international reference basket in July 2022. The former seven-country group included the United States and Switzerland. The newer PMPRB11 keeps France, Germany, Italy, Sweden and the United Kingdom, while adding Australia, Belgium, Japan, the Netherlands, Norway and Spain. Washington’s complaint is straightforward: removing two relatively high-price markets makes it harder for a manufacturer to justify a high Canadian price by pointing to what it charges elsewhere.
The current test is also more restrained than many Canadians may expect. During an annual review, staff compare the highest Canadian list price with the highest reported price among the PMPRB11 countries, not the median or lowest price. A Canadian price above that highest international level can trigger deeper scrutiny, as can an increase greater than the relevant inflation measure. The guidelines themselves do not declare a price excessive or impose an automatic ceiling. They identify cases for possible investigation, leaving a hearing panel to make the binding decision.
The Numbers Complicate Washington’s Case
Canada is not generally the cheapest patented-drug market among wealthy countries. The PMPRB reported that Canadian list prices in 2024 were, on average, higher than those in every PMPRB11 country and ranked fifth highest among 31 OECD markets examined. Roughly 31.7 per cent of medicines with sufficient international data had Canadian list prices above the highest PMPRB11 price. That evidence weakens any simple claim that Canada forces patented medicines to bargain-basement levels.
The comparison with the United States looks entirely different. PMPRB data put average U.S. list prices for patented medicines 264 per cent above Canadian levels in 2023. The highest OECD benchmark was 231 per cent above Canada in 2024, but only 40 per cent higher when the United States was excluded. In practical terms, including the U.S. in a reference basket can pull the benchmark sharply upward. Canada’s position is therefore easier to understand: using an extreme outlier as a guardrail against excessive prices could make the guardrail far less effective.
The Rules Reach Beyond Government Budgets
Prescription-drug prices flow through several parts of Canadian life. Total prescription-medicine spending was estimated at nearly $43.7 billion in 2024. Public plans covered 41 per cent, private insurers paid 38 per cent and patients paid the remaining 21 per cent out of pocket. Patented-medicine sales alone reached $22.1 billion, rising 10.9 per cent in one year as use increased and newer, higher-cost therapies entered the market.
For households, the list price is not an abstract accounting figure. It can influence the amount paid by someone without insurance, the base used to calculate a co-payment and the starting point for confidential negotiations between manufacturers and drug plans. Statistics cited by the PMPRB show that about nine per cent of Canadians reported skipping doses, delaying a refill or otherwise not following a prescription because of cost in 2021. A modest percentage change can therefore be meaningful to a provincial budget, an employer health plan or a family managing a chronic illness.
Drugmakers Link Prices to Innovation and Investment
The pharmaceutical industry’s central argument is that lower expected returns can make a smaller market less attractive. A company deciding where to launch a rare-disease therapy may consider not only Canadian sales, but whether a low public list price could affect negotiations in other countries. Washington has embraced a similar “fair share” argument, saying foreign price controls leave American patients carrying too much of the cost of global pharmaceutical innovation.
Canadian investment figures do not settle that debate, but they add context. Patent holders reported about $1.29 billion in Canadian research and development spending in 2024, up 21.1 per cent from the previous year. Even after that increase, R&D equalled 4.1 per cent of reported sales, far below the 11.7 per cent peak recorded in 1995. Among companies for which a ratio could be calculated, 46 per cent reported no Canadian R&D spending. Higher Canadian prices might improve the commercial case for investment, but the historical data do not show an automatic one-for-one link between domestic revenue and research performed in Canada.
Evidence on Patient Access Points Both Ways
Canada does receive fewer new medicines than the United States, but the meaning of that gap is disputed. A 2026 PMPRB analysis found that only 44 of 218 medicines first approved internationally from 2021 through 2024 had recorded Canadian sales by the end of 2024. Yet those medicines represented 77 per cent of total OECD sales for the group, slightly above the OECD median. Canada appears to obtain many of the commercially important launches while missing a larger number of lower-volume products.
Academic evidence is similarly nuanced. A 2024 cohort study found no overall negative effect from uncertainty surrounding the PMPRB reforms when Canada was compared with its price-reference countries. It did identify a concerning decline in two-year launches for medicines judged to have major therapeutic benefit, from 45.8 per cent to 31.3 per cent, and called for further investigation. Another study of drugs used in the United States but not Canada found that only nine of 399 qualifying products were unavailable without a Canadian alternative; the six independently assessed products in that group offered minor or no added therapeutic value. Neither side can honestly claim the access question is closed.
CUSMA Raises the Stakes Without Dictating the Outcome
The July 1 CUSMA review gives Washington political leverage, but it does not automatically convert every item in the U.S. trade-barrier report into an enforceable demand. Canada can argue that the PMPRB is an independent, quasi-judicial institution applying domestic patent law rather than discriminating against American companies. It can also point out that the current guidelines use the highest price in the 11-country basket as a screening threshold, a design that leaves manufacturers considerable room before a hearing is considered.
Ottawa nevertheless faces a delicate choice. It could defend the existing basket while offering more transparency, faster reviews and better monitoring of launches, especially for rare-disease and high-benefit therapies. It could also seek assurances that Canadian list prices will not be used to raise prices elsewhere. Washington’s own most-favoured-nation strategy anticipates downward pressure on U.S. prices and upward pressure in other wealthy markets. That makes the Canadian concern clear: a policy advertised as relief for American patients could ultimately arrive in Canada as pressure for higher pharmacy bills.
